查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995520

RNA分析/转录组学市场：依产品、技术和应用划分－2026-2032年全球市场预测

RNA Analysis/Transcriptomics Market by Product, Technology, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 RNA 分析/转录组学市场在 2025 年的价值为 65.7 亿美元，在 2026 年成长至 72.8 亿美元，到 2032 年达到 144.6 亿美元，复合年增长率为 11.93%。

主要市场统计数据
基准年 2025 65.7亿美元
预计年份：2026年 72.8亿美元
预测年份 2032 144.6亿美元
复合年增长率 (%) 11.93%

全面介绍正在重塑研究和临床环境中 RNA 分析和转录组学的科学、操作和转化因素。

RNA分析和转录组学领域正处于关键的转折点，分子生物学、定序技术和计算分析的进步正在重新定义实验和临床方法。近年来，研究界已不再局限于简单的基因表现简介，而是采用高解析度、扩充性的方法，以捕捉细胞异质性、时间动态和复杂的调控机制。因此，研究重点已从基础发现转向转化应用，为药物研发、诊断和精密农业提供资讯。为此，研究机构和商业实验室目前正优先考虑整合工作流程，以缩短从样本到获得结果的时间，同时提高可重复性和资料互通性。

高通量定序、单细胞技术创新和软体主导生态系统的融合如何重新定义转录组学的营运重点和经营模式。

转录组学领域正经历着一场变革性的转变，这反映了技术的成熟和终端使用者需求的改变。在技​​术层面，定序通量的提高和单一样本处理时间的缩短促使单细胞方法和高内涵批量分析得到更广泛的应用，从而推动实验室重新设计实验，以更深入、更详细地阐明生物系统。同时，数位PCR和改进的即时PCR方法持续为标靶检测提供快速、高灵敏度的选择，支援那些需要定量精度而非全基因组覆盖范围的诊断和检验工作流程。

评估近期美国关税措施对全球转录组学采购、供应韧性和平台选择的累积营运和策略影响。

美国近期贸易政策的变化和关税措施导致全球实验室设备、试剂及相关RNA分析组件的供应链进行调整。依赖跨境采购的企业和机构正在转变筹资策略，导致供应商合格流程延长，库存弹性也受到更多重视。关税带来的成本压力促使製造商评估替代供应商、实现特定生产过程的本地化，并重新谈判供应商合同，以维持利润率并确保供应的连续性。

详细的細項分析解释了整个转录组学工作流程中不同的产品、技术和应用路径如何产生差异化的需求讯号和研发重点。

精细化的细分观点揭示了RNA分析领域不同产品、技术和应用的需求驱动因素和推广障碍。从产品类型来看，耗材和试剂的持续需求支撑着实验室的连续性，对于需要批次间性能一致性和可靠供应的终端用户而言，这是营运中的首要任务。仪器设备仍然是资本配置决策的关键，因为平台选择决定了通量、检测相容性和下游资料特征。配套的软体和服务如同“连接组织”，将原始数据转化为可操作的洞察，并支援可扩展的分析，从而实现标准化、法规遵循和多中心协作。

决定全球转录组学应用路径、伙伴关係策略和监管合规性的区域趋势和基础设施现状。

区域趋势反映了研究经费、监管环境、产业合作和临床基础设施的差异，进而影响转录组学工具和服务的采用、支持和商业化。在美洲，由学术机构、生物技术公司和临床检查室组成的紧密生态系统正在推动先进定序平台和单细胞技术的早期应用，这体现了转化研究与商业性创新之间的紧密联繫。这种环境孕育了一个竞争激烈的服务供应商产业，支援快速技术检验、策略合作以及从发现到临床级检测的规模化应用。

在转录组学领域中，解决方案供应商之间的竞争行为、整合策略和能力优先顺序决定了供应商的选择和合作机会。

RNA分析和转录组学价值链中各公司的活动呈现出技术差异化、服务拓展和策略整合的融合趋势。仪器製造商持续在处理能力、准确性和易用性方面展开竞争，而试剂供应商则专注于稳健的化学性质、批间一致性以及能够降低检验变异性的已验证工作流程。同时，分析服务供应商和软体供应商正在加速投资于云端原生平台、标准化流程和解读层，以满足研究和临床报告的需求。

领导者面临的可操作的策略挑战，以建立具有韧性的供应链、可互通的生态系统和临床适用的转录组学解决方案。

产业领导者应采取积极主动的方式，强调其所有产品和营运组合的韧性、互通性和转化应用能力。首先，组织蓝图应优先考虑湿实验室团队、生物资讯部门和采购部门之间的跨职能协作，以确保平台选择既能带来即时的实验效益，又能实现长期的扩充性。投资决策应优先考虑模组化解决方案，以便在不牺牲检验性能的前提下逐步扩展产能，并最大限度地减少对专有组件的依赖。

采用稳健的混合方法研究设计，结合相关人员访谈、技术基准测试和情境分析，以确保为转录组学相关人员。

本研究整合了关键相关人员的意见、技术文献和检验的技术评估，对RNA分析和转录组学的发展趋势进行了全面、基于证据的分析。主要数据透过对实验室负责人、采购负责人和技术开发人员的结构化访谈收集，并辅以记录检测性能和可重复性的供应商蓝图以及同行评审的方法学研究。二级资讯来源包括说明工作流程效率和检验要求的技术白皮书、监管指导文件和基准研究。

整合策略重点，突显技术能力、运作韧性和转录组学转化研究准备之间的相互作用。

总之，RNA分析和转录组学正从探索性科学转向一个综合领域，技术选择、资料管理和供应链韧性共同决定研究和转化成果的成败。单细胞定序和高通量定序的进步正在带来新的生物学见解，但其潜力取决于严谨的工作流程、可互通的分析以及可靠的试剂和服务生态系统。对于寻求永续生产力的机构而言，营运韧性（包括多样化的资源取得、清晰的供应商支援和检验的通讯协定）与技术能力同等重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 RNA分析/转录组学市场：依产品划分

  • 耗材和试剂
  • 装置
  • 软体服务

第九章 RNA分析/转录组学市场：依技术划分

  • 数位PCR
  • 微阵列
  • 次世代定序
    • 批量转录组学
    • 单细胞转录组学
      • 基于液滴的
      • 基于微流体技术的
  • 即时PCR

第十章 RNA分析/转录组学市场：依应用划分

  • 癌症研究
  • 药物发现
  • 基因检测
    • 携带者筛检
    • 疾病诊断
    • 产前和新生儿筛检
  • 感染疾病调查
  • 工厂调查

第十一章 RNA分析/转录组学市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 RNA分析/转录组学市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 RNA分析/转录组学市场：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国RNA分析/转录组学市场

第十五章：中国RNA分析/转录组学市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Illumina, Inc.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • QIAGEN NV
  • Roche Diagnostics International AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corporation
Product Code: MRR-FB6C9E7932C7

The RNA Analysis/Transcriptomics Market was valued at USD 6.57 billion in 2025 and is projected to grow to USD 7.28 billion in 2026, with a CAGR of 11.93%, reaching USD 14.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.57 billion
Estimated Year [2026] USD 7.28 billion
Forecast Year [2032] USD 14.46 billion
CAGR (%) 11.93%

A comprehensive primer on the scientific, operational, and translational forces reshaping RNA analysis and transcriptomics across research and clinical domains

The field of RNA analysis and transcriptomics is at a pivotal juncture, driven by advances in molecular biology, sequencing technologies, and computational analytics that together are redefining experimental and clinical approaches. Over the past several years, the community has moved beyond simple gene expression snapshots to adopt high-resolution, scalable methods that capture cellular heterogeneity, temporal dynamics, and regulatory complexity. As a result, research priorities have expanded from foundational discovery to translational applications that inform drug development, diagnostics, and precision agriculture. Consequently, institutions and commercial laboratories now prioritize integrated workflows that reduce time from sample to insight while increasing reproducibility and data interoperability.

Given these dynamics, laboratory leaders and strategic planners must balance investments across recurring consumables, capital instrumentation, and software-enabled analytics. Operational decisions increasingly hinge on the ability to harmonize wet-lab protocols with robust bioinformatics pipelines, including cloud-native solutions that support large-scale transcriptomics datasets. Moreover, stakeholder expectations have shifted: funders and regulators demand transparent validation, clinical partners need standardized assays, and publishing outlets require comprehensive metadata and reproducible pipelines. In sum, the RNA analysis landscape now rewards organizations that combine technological excellence with operational rigor, comprehensive data stewardship, and clear translational roadmaps that bridge discovery and application.

How converging high-throughput sequencing, single-cell innovations, and software-driven ecosystems are redefining operational priorities and commercial models in transcriptomics

The landscape of transcriptomics is undergoing transformative shifts that reflect both technological maturation and changing end-user requirements. Technologically, improvements in sequencing throughput and reductions in per-sample processing times have enabled broader adoption of single-cell approaches and high-content bulk studies, prompting laboratories to rethink experimental design toward deeper, more granular interrogation of biological systems. Concurrently, digital PCR and refined real-time PCR methods continue to provide rapid, high-sensitivity options for targeted assays, supporting diagnostics and validation workflows that require quantitative precision rather than genome-scale breadth.

Equally important is the convergence of laboratory automation, novel microfluidic platforms, and machine learning-driven analytics, which together permit higher throughput and more reproducible data generation. This integration is shifting value from standalone instruments to coupled ecosystems where consumables, instrument firmware, and analytical software are co-optimized. Business models are adapting in response: subscription and service-centric approaches for software and cloud analytics are becoming more prominent, while manufacturers emphasize validated end-to-end solutions for clinical and regulated environments. Additionally, as collaborative networks and multi-site studies grow, standards for data exchange, quality control, and assay validation are becoming more consequential, fostering an environment where interoperability and compliance are critical competitive differentiators.

Assessing the cumulative operational and strategic consequences of recent United States tariff actions on global procurement, supply resilience, and platform selection in transcriptomics

Recent trade policy developments and tariff actions in the United States have created a recalibration across global supply chains for laboratory equipment, reagents, and related components that support RNA analysis. Companies and institutions reliant on cross-border sourcing have experienced shifts in procurement strategies, prompting extended supplier qualification processes and increased emphasis on inventory resilience. Tariff-related cost pressures have incentivized manufacturers to evaluate alternative sourcing, localize certain production steps, and renegotiate supplier contracts to preserve margin and ensure continuity of supply.

Operationally, these changes have manifested as elongated lead times for specific instrument components and specialized reagents, with procurement teams instituting contingency inventories and diversified vendor lists to mitigate disruption. Research groups have adjusted procurement cadence and, in some cases, selected platforms with broader local service footprints to reduce exposure to import-related delays. From a product-development perspective, firms are accelerating design for manufacturability initiatives that reduce reliance on geopolitically sensitive parts and that enable modular sourcing across multiple regions.

Furthermore, the cumulative effect of tariff measures has driven strategic partnerships between suppliers and distributors to smooth customs compliance and to streamline logistics. These collaborations often include co-investment in regional warehousing, harmonized documentation processes, and expanded field service networks. For translational research and clinical assay deployment, the net impact includes a greater emphasis on supply-chain transparency, vendor management, and contractual safeguards that align procurement with operational risk tolerance. Looking forward, stakeholders are likely to continue prioritizing resilience and flexibility in sourcing decisions while monitoring policy shifts that could alter cross-border trade dynamics for critical laboratory inputs.

Deep segmentation analysis explaining how distinct product, technology, and application pathways create differentiated demand signals and R&D priorities across transcriptomics workflows

A granular segmentation perspective reveals differentiated demand drivers and adoption barriers across products, technologies, and applications in RNA analysis. When viewed by product type, recurring demand for consumables and reagents underpins laboratory continuity and represents a central operational priority for end users who require consistent lot-to-lot performance and supply reliability. Instruments remain a critical focal point for capital allocation decisions because platform selection dictates throughput, assay compatibility, and downstream data characteristics. Complementary software and services form the connective tissue that converts raw measurements into actionable knowledge, enabling standardization, regulatory compliance, and scalable analytics for multi-site studies.

By technology, the ecosystem includes digital PCR and real-time PCR as robust tools for targeted quantification and validation, while microarray technologies retain a niche for specific comparative expression studies. Next Generation Sequencing has emerged as the dominant high-resolution approach, with bulk transcriptomics serving broad discovery use cases and single cell transcriptomics enabling interrogation of heterogeneous tissues and rare cell types. Within single-cell studies, droplet-based methods provide high-throughput cell partitioning suitable for large-scale atlasing projects, whereas microfluidics-based platforms offer precise control for specialized assays and multiomic integrations. Each technological class carries distinct workflow implications: sample preparation requirements, computational needs, and quality control benchmarks vary and therefore influence adoption curves across organizations.

Application-driven segmentation further clarifies prioritization. Cancer research continues to demand deep transcriptomic profiling to elucidate tumor heterogeneity and therapeutic resistance mechanisms, while drug discovery leverages expression signatures and pathway analyses for target identification and pharmacodynamics. Genetic testing programs require robust, validated assays across carrier screening, disease diagnostics, and prenatal and newborn applications, with particular emphasis on assay sensitivity, specificity, and regulatory readiness. Infectious disease research relies on rapid, high-sensitivity assays and scalable sequencing to track pathogens and host responses, and plant research increasingly adopts transcriptomic tools to accelerate trait discovery and stress-response characterization. Understanding these intersecting segmentation axes helps organizations align product portfolios, R&D investments, and commercial strategies to the nuanced needs of each user community.

Regional dynamics and infrastructure realities that determine adoption pathways, partnership strategies, and regulatory alignment for transcriptomics across global geographies

Regional dynamics shape how transcriptomics tools and services are adopted, supported, and commercialized, reflecting differences in research funding, regulatory landscapes, industrial partnerships, and clinical infrastructure. In the Americas, a dense ecosystem of academic centers, biotech companies, and clinical laboratories drives early adoption of advanced sequencing platforms and single-cell technologies, with strong ties between translational research and commercial innovation. This environment fosters rapid technology validation, strategic collaborations, and a competitive service-provider sector that supports scaling from discovery to clinical-grade assays.

Across Europe, the Middle East, and Africa, adoption patterns are heterogeneous: leading research hubs and national initiatives accelerate uptake of high-throughput platforms and standardized workflows, while broader regional disparities reflect variable access to capital and laboratory infrastructure. Regulatory frameworks in some European jurisdictions place particular emphasis on clinical validation and data privacy, prompting suppliers to emphasize compliance and localized support. Meanwhile, collaborative consortia and pan-regional projects help disseminate best practices and enable resource-sharing for high-cost technologies.

In the Asia-Pacific region, expanding public and private investment in life sciences has elevated demand for both instruments and consumables. Several countries are developing strong domestic manufacturing and service capabilities, which influences procurement preferences and price sensitivity. Rapidly growing research communities and clinical genomics programs are driving adoption across pharmaceutical, agricultural, and public health domains. Taken together, these regional dynamics necessitate differentiated commercial strategies: multinational suppliers must tailor go-to-market approaches, service models, and partnerships to align with local regulatory requirements, infrastructure maturity, and customer support expectations.

Competitive behaviors, integration strategies, and capability priorities among solution providers that determine vendor selection and partnership opportunities in transcriptomics

Company activity across the RNA analysis and transcriptomics value chain reflects a blend of technological differentiation, service expansion, and strategic consolidation. Instrument manufacturers continue to compete on throughput, accuracy, and ease of use, while reagent suppliers focus on robust chemistry, lot consistency, and validated workflows that reduce assay variability. At the same time, analytics providers and software vendors are accelerating investments in cloud-native platforms, standardized pipelines, and interpretive layers that address both research and clinical reporting needs.

Strategic behaviors include targeted M&A to secure proprietary chemistries or analytics assets, partnership-based go-to-market approaches that bundle instruments with consumables and data services, and expanded field service networks to support global deployment. Companies that successfully integrate hardware, chemistry, and software often gain a competitive edge by reducing end-user validation burden and enabling faster time to insight. Conversely, specialist providers that focus on niche assay chemistries, microfluidic innovations, or advanced bioinformatics can capture value through collaborations with platform vendors and contract research organizations.

For customers, vendor selection now involves assessment of long-term support, interoperability, and the breadth of validated applications. Procurement decisions increasingly weigh roadmap transparency, regulatory readiness, and the availability of training and application support. The evolving competitive landscape favors organizations that can demonstrate demonstrable reproducibility, comprehensive validation datasets, and pragmatic pathways for clinical translation or industrial scale-up.

Actionable strategic imperatives for leaders to build resilient supply chains, interoperable ecosystems, and clinically translatable transcriptomics offerings

Industry leaders should adopt a proactive stance that emphasizes resilience, interoperability, and translational readiness across product and operational portfolios. First, organizational roadmaps must prioritize cross-functional alignment between wet-lab teams, bioinformatics units, and procurement to ensure that platform selections deliver both immediate experimental benefits and long-term scalability. Investment decisions should favor modular solutions that allow incremental expansion of capacity and that minimize lock-in to proprietary components without sacrificing validated performance.

Second, firms should double down on supply-chain transparency and diversified sourcing to mitigate geopolitical and tariff-related risks. This includes qualifying alternative suppliers, securing strategic inventory buffers for critical reagents, and negotiating service-level agreements that provide clarity on lead times and support. Third, vendors and service providers should emphasize open standards, common data formats, and validated APIs to facilitate interoperability across instruments, LIMS, and analytics platforms, reducing integration overhead for end users.

Fourth, commercial teams should structure offerings around outcome-focused value propositions that combine instrumentation, validated consumables, and analytics services. For translational initiatives, companies must build or partner for robust clinical validation pathways, regulatory expertise, and reproducible documentation that meet certification requirements. Finally, leaders should invest in workforce enablement-training programs, methodological workshops, and application support-to ensure that customers realize the full potential of transcriptomics technologies while maintaining high standards of data quality and assay reproducibility.

Robust mixed-methods research design combining stakeholder interviews, technical benchmarking, and scenario analyses to ensure reproducible and actionable insights for transcriptomics stakeholders

This research synthesized primary stakeholder input, technical literature, and validated technology assessments to produce a comprehensive, evidence-based analysis of RNA analysis and transcriptomics trends. Primary data were gathered through structured interviews with laboratory directors, procurement specialists, and technology developers, complemented by vendor roadmaps and peer-reviewed methodological studies that document assay performance and reproducibility. Secondary sources included technical white papers, regulatory guidance documents, and benchmarking studies that describe workflow efficiencies and validation requirements.

Analytical methods combined qualitative thematic coding of stakeholder interviews with comparative technology profiling and scenario-based supply-chain analysis. Key performance attributes-such as assay sensitivity, throughput, workflow complexity, and computational requirements-were mapped across product and technology segments to highlight compatibility constraints and enabling capabilities. Where appropriate, case examples and real-world operational practices were used to illustrate how institutions navigate platform selection and deployment. Throughout the process, findings were cross-validated via expert review cycles to ensure technical accuracy and practical relevance for both research and clinical audiences.

Synthesis of strategic priorities highlighting the interplay of technological capability, operational resilience, and translational readiness in transcriptomics

In conclusion, RNA analysis and transcriptomics are transitioning from exploratory science to an integrated field where technological selection, data stewardship, and supply-chain resilience jointly determine research and translational success. Advances in single-cell and high-throughput sequencing are unlocking new biological insights, yet their promise depends on rigorous workflows, interoperable analytics, and reliable reagent and service ecosystems. Operational resilience-spanning diversified sourcing, clear vendor support, and validated protocols-has become as important as technical capability for institutions seeking sustained productivity.

Looking ahead, stakeholders that align investments across consumables, instruments, and analytics while maintaining a focus on reproducibility and regulatory readiness will be best positioned to translate discovery into impact. Collaboration between manufacturers, service providers, and end users will accelerate validation pathways and lower barriers to clinical adoption. Ultimately, the most successful organizations will be those that treat transcriptomics not as a single technology choice but as a systems-level capability that integrates laboratory practice, computational rigor, and supply-chain discipline to deliver reliable, actionable biological insights.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Analysis/Transcriptomics Market, by Product

  • 8.1. Consumables & Reagents
  • 8.2. Instruments
  • 8.3. Software & Services

9. RNA Analysis/Transcriptomics Market, by Technology

  • 9.1. Digital PCR
  • 9.2. Microarray
  • 9.3. Next Generation Sequencing
    • 9.3.1. Bulk Transcriptomics
    • 9.3.2. Single Cell Transcriptomics
      • 9.3.2.1. Droplet Based
      • 9.3.2.2. Microfluidics Based
  • 9.4. Real Time PCR

10. RNA Analysis/Transcriptomics Market, by Application

  • 10.1. Cancer Research
  • 10.2. Drug Discovery
  • 10.3. Genetic Testing
    • 10.3.1. Carrier Screening
    • 10.3.2. Disease Diagnostics
    • 10.3.3. Prenatal & Newborn Testing
  • 10.4. Infectious Disease Research
  • 10.5. Plant Research

11. RNA Analysis/Transcriptomics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. RNA Analysis/Transcriptomics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. RNA Analysis/Transcriptomics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States RNA Analysis/Transcriptomics Market

15. China RNA Analysis/Transcriptomics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. 10x Genomics, Inc.
  • 16.6. Agilent Technologies, Inc.
  • 16.7. Bio-Rad Laboratories, Inc.
  • 16.8. Danaher Corporation
  • 16.9. Illumina, Inc.
  • 16.10. Oxford Nanopore Technologies Ltd.
  • 16.11. Pacific Biosciences of California, Inc.
  • 16.12. QIAGEN N.V.
  • 16.13. Roche Diagnostics International AG
  • 16.14. Takara Bio Inc.
  • 16.15. Thermo Fisher Scientific Inc.
  • 16.16. Zymo Research Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 130. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 132. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 134. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 151. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 156. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 158. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 162. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 163. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)